
Opinion|Videos|August 16, 2024
Navigating the Treatment Paradigm for Vitiligo: Efficacy, MOA, and Long-Term Use of FDA-Approved Topical Ruxolitinib
Author(s)Ted Lain, MD, MBA, FAAD
Ted Lain, MD, MBA, FAAD discusses navigating the treatment paradigm for vitiligo.
Advertisement
Episodes in this series

Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement

















